Immuron Limited (IMRN) furnishes ASX ‘Clinical Trial Update’ to U.S. market

Rhea-AI Filing Summary

Immuron Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with access to an announcement it released on the Australian Securities Exchange. The filing states that the company published a public notice on October 31, 2025 titled “Clinical Trial Update”, and that this announcement is attached to the Form 6-K as Exhibit 99.1. The company also clarifies that this Form 6-K, including the exhibit, is being furnished rather than filed under U.S. securities laws and will not be incorporated into other Securities Act filings unless specifically referenced.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025

Commission File Number: 001-38104

IMMURON LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

IMMURON LIMITED

EXPLANATORY NOTE

Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on October 31, 2025 titled:

	-	Clinical Trial Update
	-

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Clinical Trial Update

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IMMURON LIMITED
Date: October 31, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3

FAQ

What did Immuron Limited (IMRN) submit in this Form 6-K?

Immuron Limited submitted a Form 6-K to furnish a public notice it released on the Australian Securities Exchange, titled “Clinical Trial Update”, to U.S. investors.

What is included as an exhibit in Immuron Limited’s (IMRN) October 2025 Form 6-K?

The Form 6-K includes Exhibit 99.1, which is Immuron Limited’s ASX announcement titled “Clinical Trial Update” dated October 31, 2025.

Does this Immuron (IMRN) Form 6-K count as a filed document under the Exchange Act?

The company states that this Form 6-K, including its exhibit, is furnished and is not deemed to be “filed” for purposes of the Securities Exchange Act of 1934.

Will Immuron’s (IMRN) clinical trial update be automatically incorporated into other SEC filings?

No. Immuron notes that this Form 6-K and its exhibit will only be incorporated by reference into other Securities Act filings if they are expressly referred to in those filings.

Who signed Immuron Limited’s (IMRN) October 31, 2025 Form 6-K?

The Form 6-K was signed on behalf of Immuron Limited by Phillip Hains, who is identified as the Company Secretary.